Stocks TelegraphStocks Telegraph
Stock Ideas

OCX Stock Performance and Key Statistics

NASDAQ : OCX

OncoCyte

$3.20
0.47+17.22%
At Close 4:00 PM
Not Actively Trading
68.29
BESG ScoreESG Rating

stock performance chart

OCX Fundamental Analysis

Based on recent data, OncoCyte Corporation (OCX) shows an Average True Range (ATR) of 0.25 and an Enterprise Value of 13.79M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into OCX's underlying financial health and market activity.

ATR0.25
Enterprise Value13.79M
Avg Vol (3 Months)-
Avg Vol (10 Days)-

OCX Technical Analysis Indicators

OncoCyte Corporation (OCX) technical indicators as of April 23, 2026: the SMA 20 is 5.67%, SMA 50 at 7.91%, and SMA 200 at 13.53%. The RSI 14 value is 58.27, suggesting its current momentum. These technical analysis signals help assess OCX's price trends and potential future movements.

SMA 205.67%
SMA 507.91%
SMA 20013.53%
RSI 1458.27

OCX Stock Performance Overview

OncoCyte Corporation (OCX) stock performance overview as of April 23, 2026: The 52-week high is $4.14 (currently -32.63% below), and the 52-week low is $2.56 (currently 66.49% above). Over the past year, OCX's performance is 16.36%, compared to the S&P 500's 22.86% change.

52-Week High4.14
52-Week High Chg-32.63%
52-Week Low2.56
52-Week Low Chg+66.49%
S&P 500 52-Week Chg22.86%

OncoCyte Corporation (OCX) Historical Stock Performance

According to market data, OncoCyte Corporation (OCX) stock's recent performance metrics show that over the last month, OCX is 14.7%, with a Year-to-Date (YTD) performance of 34.45%. Over the past year, the stock has seen a 16.36% change. These figures summarize OCX's price movements across various periods, reflecting its historical returns.

Period1 Week1 MonthQuarterHalf Year1 YearYTD
High4.144.144.144.144.14N/A
Low2.852.562.562.562.56N/A
Performance+15.94%+14.70%-13.51%+33.89%+16.36%+34.45%

Industry Analysis and Valuation

According to current financial data, OCX stock's P/E (TTM) ratio is -2.04, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for OCX, including P/S (22.57), P/B (-3.26), and P/FCF (-4.18), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.

ValuationOCXSector MedianIndustry AvgS&P 500
P/E (TTM)-2.04-1.22-5.1232.59
P/S (TTM)22.573.69464.325.98
P/B (TTM)-3.263.810.714.68
P/FCF (TTM)-4.1869.05-462.5632.51

Frequently Asked Questions

How is OCX price-to-earnings ratio currently?
OCX has a current P/E ratio of -2.04
How are OCX's price-to-sale and price-to-book ratios?
The OCX stock has a trailing twelve month price-to sales (P/S) ratio of 22.57 while its price-to-book (P/B) value is -3.26.
Is OncoCyte Corporation's price-to-cashflow ratio high or low?
OCX's price-to-free-cashflow (P/FCF) ratio is -4.18, an indicator that is currently being trending upward.
What's current simple moving average (SMA) for OCX?
Based on OCX's recent bid, its distance from 20 days simple moving average is 5.67%. It is 7.91% apart from 50 days simple moving average, and it is 13.53% apart from 200 days simple moving average.
What is the 52-week price range for OCX?
The 52-week high for OCX is $4.75 which is -32.63% away from the current price level whereas the distance of that from the 52-week low of $1.92 stands at 66.49%.
An overview of OCX's stock performance: how did it fare?
The performance of OCX stock was not encouraging with most of its significant price indicators in green. OncoCyte Corporation(NASDAQ: OCX) shares have moved upward +17.22% or $0.47 in the latest trading session and have gained 34.45% year-to-date (YTD). The stock has gained nearly 16.36% over the past year. After moving -13.51% over the trailing 3-month period, the stock is 33.89% higher in the 6-month period. Looking at its performance over the shorter term, it'sgained 15.94% a week and 14.7% a month.
What is OCX's 14-day relative strength index (RSI)?
The current 14-day RSI for OCX stock is 58.27. Investors and traders alike rely on the relative strength index, or RSI, as an oscillating indicator. In terms of values, the RSI operates within a range ranging from 0 to 100. A rising RSI line indicates strength in the shares. As the RSI line falls, the opposite occurs. It is possible to examine different time periods when using the RSI indicator. Shorter time frames can cause the RSI to be more volatile. Most traders pay close attention to the marks between 30 and 70 on the RSI scale. When the stock price moves over 70, it is often considered to be an indicator of overbought conditions. Dropping below 30 indicates oversold territory. These levels are often used by traders to forecast stock price reversals.
For OCX, what is the average true range (ATR) for the past two weeks?
ATR stands for Average True Range, which may be useful when traders or investors are assessing technical inventory. Currently, OncoCyte Corporation (OCX) has a 14-day ATR of 0.25.
What is OCX's current enterprise value?
After closing at $2.73 with 28.6M of its shares outstanding, the current enterprise value of OCX is roughly 13.79M.
Over the past year, how has the stock price of OCX changed?
OncoCyte Corporation (NASDAQ: OCX) is up 16.36% when it comes to the percentage price change over the past 52-weeks. The percentage price change came less than that of broader S&P 500 index that came at a fall of 22.86%. OCX stock price is also up 34.45% on its value in year-to-date trading.
What is the average trading volume for OCX shares?
The number outstanding shares of OCX is 28.6M, and of these 27.12% shares are freely available for trading. On average, OCX stock has traded - shares per day for the past 10 days. A total of 100.56K shares changed hands during the last trading session with the average session volume of 76.06K shares.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph